Royalty Report: Medical, Device, Delivery – Collection: 27723


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Medical
  • Device
  • Delivery
  • Surgical
  • Drugs
  • Disease
  • Therapeutic
  • Coating

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27723

License Grant
The company granted to us exclusive, world-wide rights under intellectual property, including patents, trade secrets and know-how, to develop and commercialize products using the DUROS drug delivery technology in the fields of the delivery of drugs by catheter to the central nervous system to treat selected central nervous system disorders, the delivery of drugs by catheter to the middle and inner ear, the delivery of drugs by catheter into the pericardial sac of the heart, the delivery of selected drugs by catheter into vascular grafts and the delivery of selected cancer antigens.
License Property
The DUROS system is a miniature drug-dispensing pump made out of titanium which can be as small as a wooden matchstick.
Field of Use
This agreement pertains in the fields of the delivery of drugs by catheter.

IPSCIO Record ID: 1850

License Grant
The Company entered into an agreement for the license for Epidural catheters used to infuse drugs into the epidural space in the spinal column (vi) Implantable infusion ports and pumps and their attached catheters used for drug therapy and access to the vascular system (vii) Intra-aortic balloon catheters (viii) Drainage catheters used to drain chest cavities, surgical incisions, wounds and abscesses.
Field of Use
Fields of Application)
(v) Epidural catheters used to infuse drugs into the epidural space in the spinal column.
(vi) Implantable infusion ports and pumps and their attached catheters used for drug therapy and access to the vascular system.
(vii) Intra-aortic balloon catheters.
(viii) Drainage catheters used to drain chest cavities, surgical incisions, wounds and abscesses.

IPSCIO Record ID: 28439

License Grant
The Licensor, government organization, desires to transfer inventions to the private sector through commercialization Licenses to facilitate the commercial development of products and processes for public use and benefit.  The Licensor granted a nonexclusive License under the Licensed Patent Rights in the United States of America including its Territories, Commonwealths and Possessions to use and have used the Licensed Process to administer Drug to treat gliomas. Licensee does not have the right to subLicense.
License Property
U.S. Patent 5,720,720 Convection-Enhanced Drug Delivery including 1L13-PE38QQR, for treating gliomas delivered or recommended to be delivered using the Licensed Process.
Field of Use
Licensed Fields of Use Nonexclusive for using the Licensed Process to administer Drug to treat gliomas.

IPSCIO Record ID: 266858

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensor Intellectual Property, to research and develop, make, have made, use, sell, offer for sale, import, export, and otherwise commercialize any Licensed Product within the Field in the Territory.   The license granted  is exclusive.
License Property
Licensor owns or has rights to certain information and data relating to the development of Gacyclidine, including rights in the Field and has conducted certain pre-clinical investigations regarding same.

Licensor has licensed certain rights to Active Agents as locally delivered therapeutics in the Field with rights to sublicense to Licensee pursuant to an Amended and Restated Agreement between Institut National de la Sante et de la Recherche Medicate and Licensor.

Licensor owns or has rights to certain proprietary technology for site-specific and time-released delivery of drugs, defined as the Licensor Drug Delivery Platforms.

Gacyclidine shall mean cis-1-(2-thienyl)-1-N-piperidinyl-2-methycyclohexane hydrochloride in its racemic form.

Licensed Product shall mean any pharmaceutical formulation containing an Active Agent or,  a product incorporating an active ingredient and a Licensor Drug Delivery Platform pursuant to Licensee opting to develop such Licensed Product, in any case for use in the Field.

Licensor Drug Delivery Platforms shall mean the following drug delivery technology or methods owned or Controlled by Licensor  the DUROS Technology Platform,  the SABER Delivery System,  the DORIN Biodegradable Implant Technology,  the MICRODUR Biodegradable Microparticle Technology, and any other drug delivery technology owned or Controlled by Licensor as of the Effective Date.

Field of Use
Field shall mean local delivery of therapeutic agent(s) to the middle or inner ear for the following indications  treatment of tinnitus; and,  to improve post-operative recovery and tolerance of surgical implantation of devices such as cochlear implants in the inner ear.

The Intellectual Property is to market and sell products for the treatment of certain inner ear disorders including chronic tinnitus (ringing in the ears).  Over eight million people in the U.S. suffer from chronic ringing, hissing, buzzing or other noises in one or both ears, a condition known as tinnitus.

IPSCIO Record ID: 268269

License Grant
Licensor will manufacture and supply the Implantable System for Remodulin, and Licensee will manufacture and supply Remodulin for use in the system. Each party will perform certain additional activities to support the commercialization of the Implantable System for Remodulin.
License Property
The system incorporates a proprietary Licensor intravascular infusion catheter with Medtronic’s SynchroMed® II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of pulmonary arterial hypertension (PAH). We believe this technology has the potential to reduce many of the patient burdens and other complications associated with the use of external pumps to administer prostacyclin analogues.
Field of Use
The Parties wish to collaborate on the commercialization in the United States of the delivery of Remodulin® (treprostinil) injection drug to patients with pulmonary arterial hypertension using Medtronic implantable pumps, catheters, and programmers, and related Medtronic accessories.

IPSCIO Record ID: 2991

License Grant
Trial in the Company's U.S. case based on the Kastenhofer patent in Federal District Court in California concluded in October 2007 with a jury finding that the patent was invalid. The licensee was found to infringed a patent covering features of the chemically treated and multi-layered guide wire tubes that enable catheters to slide into place. The jury also found for patent owner on its counterclaim that sale by the Company of its balloon catheters and stent delivery systems infringe owner's Fontirroche patent. The Court has denied the Company's post trial motions.
License Property
Fontirroche patents pertain to designs for balloon catheters and stent delivery systems.

IPSCIO Record ID: 164315

License Grant
The Irish Licensor grants the Licensee of Bermuda an exclusive license to the Licensors Technology for all research, development, and commercial purposes solely in the Field, but not beyond the Field.

Licensor grants the Licensee a non-exclusive license, or, if applicable, sublicense, to use the Licensors Trademarks, upon or in relation to the promotion, marketing, advertising, sale or offering for sale of the Licensors Royalty Products.

License Property
The trademark license includes Medipad(TM) and Elan(R).

The Licensors Medipad System Patent Portfolio includes, among others, patents and applications for Method and Device for Entrapping a Volume of Gas in a Liquid Drug Container,  Improved Method of Packaging a Drug Delivery Kit,  Cartridge-Based Drug Delivery Device and Medicament Delivery Device.

Medipad/TM/ is a lightweight, disposable drug delivery system, which combines the simplicity of a patch with the extensive delivery capabilities of an infusion pump.

Field of Use
The field of use is for the research, development, and commercialization of Iron chelating agents and the Substitute Compounds.

IPSCIO Record ID: 26795

License Grant
The Company has agreements with certain of its suppliers of coatings for its micro catheter, access and delivery products.  There are various undisclosed Licensors.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.